Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Capvaxive
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Capvaxive (pneumococcal 21-valent conjugate vaccine, PCV21) is a biologic vaccine developed by Merck for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults aged 18 and older. It contains capsular polysaccharides from 21 *Streptococcus pneumoniae* serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) individually conjugated to the CRM197 carrier protein (a nontoxic diphtheria toxin). The vaccine was FDA-approved in June 2024 and is specifically designed to cover serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 65 and older. The VA Sierra Nevada Health Care System is conducting a Phase 4 clinical trial to evaluate the booster immune response of Capvaxive in immunocompromised veterans who have previously received the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
- Brand names
- Capvaxive
- Other names
- pneumococcal 21-valent conjugate vaccinepneumococcal21-valent conjugate vaccinepneumococcal-21-valent conjugate vaccinePCV21PCV-21PCV 2121-valent pneumococcal conjugate vaccine
02
Targets
Capsular polysaccharides of Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, de-O-acetylated 15B, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B
Beyond the preview
Go deeper on Capvaxive.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Capvaxive.